Your session is about to expire
← Back to Search
Amoxicillin for Penicillin Allergy
Phase 4
Waitlist Available
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10-14 months after amoxicillin challenge
Awards & highlights
Summary
This trial is looking at the feasibility of delabeling patients who have a reported penicillin allergy in a pediatric primary care clinic.
Eligible Conditions
- Penicillin Allergy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 10-14 months after amoxicillin challenge
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10-14 months after amoxicillin challenge
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Penicillin Allergy Labeling in Subjects With Negative Amoxicillin Challenge
Side effects data
From 2023 Phase 4 trial • 23 Patients • NCT050103049%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Pediatric Patients With a History of Penicillin Allergy
Trial Design
1Treatment groups
Experimental Treatment
Group I: Pediatric Patients with a history of penicillin allergyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Amoxicillin
2017
Completed Phase 4
~7780
Find a Location
Who is running the clinical trial?
American College of Allergy, Asthma and ImmunologyOTHER
3 Previous Clinical Trials
31 Total Patients Enrolled
University of Texas Southwestern Medical CenterLead Sponsor
1,076 Previous Clinical Trials
1,056,326 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Pediatric Patients with a history of penicillin allergy
Awards:
This trial has 3 awards, including:- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger